The Priority Review

Regulation Brief

FDA issues priority review voucher for EMCITATE (tiratricol)

The FDA announced that EMCITATE (tiratricol), approved September 28, 2026, manufactured by Rare Thyroid Therapeutics International AB, meets the criteria for a priority review voucher. The tablet is indicated for treating peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome).

Primary source

Federal Register notice, October 28, 2026

Issuance of Priority Review Voucher; Rare Pediatric Disease Product; EMCITATE (Tiratricol)

Read the source: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; EMCITATE (Tiratricol) federalregister.gov

Machine-summarized from the source above; not independently reported. How we use automation